Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John F. Engelhardt, Michael Goodheart
Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John F. Engelhardt, Michael Goodheart
Michael J. Goodheart
Lef-1 mRNA levels were statistically elevated in cases of ovarian, fallopian tube or peritoneal cancer when compared to non-cancerous controls. Among cancer cases, levels of Lef-1 were statistically different between stage and histology. Lef-1 overexpression may be predictive of poor overall survival. These findings suggest that Lef-1 overexpression may contribute to ovarian, fallopian tube and peritoneal carcinogenesis, and that further investigation is warranted.
The Relationship Between Vascularity, P53 Gene Mutations And Distant Metastatic Disease In Epithelial Ovarian Carcinoma, Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed, Michael Goodheart
The Relationship Between Vascularity, P53 Gene Mutations And Distant Metastatic Disease In Epithelial Ovarian Carcinoma, Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed, Michael Goodheart
Michael J. Goodheart
Mutations of the p53 tumor suppressor gene are associated with large differences (>7 vessels/HPF) in Microvessel density (MVD) counts between primary and metastatic tumor sites in patients with epithelial ovarian cancer. These data are consistent with models demonstrating p53 mutation functions directly to influence angiogenesis. This information supports continued therapy and research involving angiogenesis inhibitors in patients with ovarian cancer, especially in the setting of increased differences in MVD between primary and metastatic sites.
Comparison Of P53 Mutation Status, Primary Cytoreductive Surgical Outcomes, And Overall Survival In Patients With Ovarian Cancer, David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf, Michael Goodheart
Comparison Of P53 Mutation Status, Primary Cytoreductive Surgical Outcomes, And Overall Survival In Patients With Ovarian Cancer, David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf, Michael Goodheart
Michael J. Goodheart
Optimal surgical cytoreduction continues to be an important prognostic variable in patients with ovarian cancer independent of p53 mutational status. Among patients with suboptimal cytoreduction a p53 mutation may offer a survival advantage.
Zmiz1 Is Overexpressed In Epithelial Ovarian Cancer And Associated With P53 Gene Mutations, Niyati J. Nadkarni, Laura M. Rogers, Megan Samuelson, Traci Neff, David P. Bender, Amina Ahmed, Koen De Geest, Anna Button, Adam Dupuy, Michael Goodheart
Zmiz1 Is Overexpressed In Epithelial Ovarian Cancer And Associated With P53 Gene Mutations, Niyati J. Nadkarni, Laura M. Rogers, Megan Samuelson, Traci Neff, David P. Bender, Amina Ahmed, Koen De Geest, Anna Button, Adam Dupuy, Michael Goodheart
Michael J. Goodheart
Zmiz1 staining is elevated in patients with epithelial ovarian cancer. Tumors that are Zmiz1 positive are associated with mutations of the p53 gene. Zmiz1 overexpression may be associated with decreased survival in patients with epithelial ovarian cancer. Additional studies are needed to more clearly determine the role of Zmiz1 in patients with epithelial ovarian cancer.